Importance of dendritic cells in pathogenesis and therapy of conjunctival melanoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00016901

Enrollment

Registered

2019-04-08

Start date

2020-01-01

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C69.0

Interventions

Group 1: BRAF mutations have been found in more than 70% of dermal melanomas and in up to 50% of CMs (Conjunctival melanoma). In our ophthalmopathological archive, an extensive amount of CM tissue is

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Tissue from patients with conjunctival melanoma, which is histologically confirmed.

Exclusion criteria

Exclusion criteria: Pretreatment with neoadjuvant immunotherapies, local chemotherapy or radiotherapy

Design outcomes

Primary

Measure	Time frame
The aim of the study is to gain a better understanding of dendritic cell subtypes and BRAF expression in conjunctival melanoma.	—

Countries

Germany

Contacts

Public ContactLudwig Heindl

Universitätsaugenklinik Köln

ludwig.heindl@uk-koeln.de0221 478 4313

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026